Key result
Thrombolysis achieves ~84% initial success in subclavian vein thrombosis, with oral anticoagulation providing long-term benefit.
Why the study?
What are the outcomes of different treatment modalities for subclavian vein thrombosis based on etiology?
Population
32 patients with subclavian vein thrombosis, including 19 with secondary SVT and 13 with Paget-Schroetter…
Design
Cohort
Authors
Loading...
Supports thrombolysis plus anticoagulation for subclavian vein thrombosis; hypothesis-generating for etiology-specific adjunctive strategies pending randomized trials.
Cohort (n=32)
No
What are the outcomes of different treatment modalities for subclavian vein thrombosis based on etiology?
Thrombolysis and oral anticoagulation provide very good results for subclavian vein thrombosis, whereas angioplasty and stenting offer limited long-term benefit in secondary SVT.
Beygui et al. (1997) conducted a cohort in Subclavian vein thrombosis (SVT) (n=32). Thrombolysis and adjunctive treatments (angioplasty, stenting, surgery, anticoagulation) was evaluated on Initial treatment success with thrombolysis (complete obliteration of clot). Initial treatment success with thrombolysis was achieved in 84% of patients with subclavian vein thrombosis, with oral anticoagulation providing good long-term results.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: